Digene's papillomavirus test cleared in US:
This article was originally published in Clinica
Executive Summary
The FDA has given marketing clearance for Digene's Hybrid Capture II, a DNA-based test for the human papillomavirus (HPV) - the cause of almost all cervical cancer. Dr Attila Lorincz, scientific director of the Beltsville, Maryland-based company, said that the test: "detects up to 90% to 95% of high grade cervical disease. The Pap smear, on the other hand, may miss 20% to 30% of cervical cancers and their pre-malignant lesions." Studies in progress should reveal whether or not supplementing Pap smears with HPV testing not only prevents women with treatable disease being missed, but also allows smears to be done less frequently, thereby reducing the cost of screening.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.